A COMPARISON OF SATB2 EXPRESSION RESULTS WITH CK20 AND CDX2 IN METASTATIC COLORECTAL CARCINOMA CASES

Basit Öğe Kaydı
dc.authoridAKATLI, AYSE NUR/0000-0002-9677-2456
dc.authoridBozdag, Zehra/0000-0002-0477-2513
dc.authorwosidAKATLI, AYSE NUR/ABH-4455-2020
dc.authorwosidBozdag, Zehra/AAG-5279-2020
dc.contributor.authorBozdag, Zehra
dc.contributor.authorAkatli, Ayse Nur
dc.date.accessioned2024-08-04T20:45:51Z
dc.date.available2024-08-04T20:45:51Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: SATB2 (The special AT-rich sequence-binding protein 2) is the new DNA binding protein and nuclear transcrip-tion factor. In normal epithelial tissues, the SATB2 protein is specifically expressed in the nuclei of the lower gastrointestinal (GI) tract epithelial cells. The elective expression of SATB2 in the lower GI tract implies that it can be used as a diagnostic marker for metastatic colorectal carcinoma (CRC). Materials and methods: Immunohistochemical (IHC) analysis was performed by applying SATB2, CK20 and CDX2 in 96 meta-static CRC cases (51 liver, 22 lung, 19 ovarian, 3 skin and 1 uterine myometrial tissue) with various origins. The aim is to evaluate the diagnostic value of SATB2 alone, and the double and triple combinations of SATB2 with CK20 and CDX2. Results: Out of 96 metastatic colon carcinoma cases, 94 (97.9%) had positive SATB2 expressions. It was found that 93.7% (90/96) of the cases had expression with CK 20 and CDX2. The sensitivity of SATB2 alone was 97.92%, and the sensitivity of CK20 and CDX2 alone was the same, i.e. 93.75%. This rate was also higher in the double combination of SATB2 with CDX2 and CK20 in comparison to the double combination of CK20 and CDX2. The sensitivity of SATB2 and CK20 combination was 98.8%, which was higher than that of CK20 and CDX2 combination. Conclusions: Our results support the requirement of including SATB2 in the IHC panel for metastatic CRC cases.en_US
dc.identifier.doi10.19193/0393-6384_2019_2_163
dc.identifier.endpage1071en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85063627919en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1067en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2019_2_163
dc.identifier.urihttps://hdl.handle.net/11616/98744
dc.identifier.volume35en_US
dc.identifier.wosWOS:000462575000061en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCDX2en_US
dc.subjectCK20en_US
dc.subjectcolorectal carcinoma metastasisen_US
dc.subjectSATB2en_US
dc.titleA COMPARISON OF SATB2 EXPRESSION RESULTS WITH CK20 AND CDX2 IN METASTATIC COLORECTAL CARCINOMA CASESen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu